

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP XenoSure sales growth:

For the three months ended June 30, 2019

XenoSure sales as reported

\$ 5,948

Impact of currency exchange rate fluctuations

146

Adjusted sales for the three months ended June 30, 2019

\$ 6,094

For the three months ended June 30, 2018

XenoSure sales as reported

\$ 5,977

Adjusted XenoSure sales increase for the three months ended June 30, 2019

\$ 117

2%